9.04
0.77%
-0.07
After Hours:
9.04
Lexeo Therapeutics Inc stock is traded at $9.04, with a volume of 460.46K.
It is down -0.77% in the last 24 hours and down -21.46% over the past month.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
See More
Previous Close:
$9.11
Open:
$9.08
24h Volume:
460.46K
Relative Volume:
1.33
Market Cap:
$301.19M
Revenue:
-
Net Income/Loss:
$-62.31M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.24%
1M Performance:
-21.46%
6M Performance:
-42.35%
1Y Performance:
+0.00%
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Novo Holdings A S Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore - The Economic Times
LXP Industrial Trust (NYSE:LXP) PT Raised to $11.00 at Evercore ISI - Defense World
Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Quest Partners LLC Acquires 11,597 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World
Get in on Lexicon Pharmaceuticals Inc’s (LXRX) buy-in window today! - SETE News
LXP Industrial Trust price target raised to $11 from $10 at Evercore ISI - TipRanks
Investor’s Delight: Lexicon Pharmaceuticals Inc (LXRX) Closes Strong at 1.70, Up 1.80 - The Dwinnex
Objective long/short (LXEO) Report - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus Price Target from Analysts - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World
Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR
The Globe and Mail - The Globe and Mail
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Top investors say Lexeo Therapeutics Inc. (LXEO) ticks everything they need - SETE News
The Lexeo Therapeutics Inc. (LXEO) had a good session last reading, didn’t it? - US Post News
Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 16.9% - MarketBeat
Trading (LXEO) With Integrated Risk Controls - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts - MarketBeat
Chardan Capital Comments on Lexeo Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:LXEO) - MarketBeat
Vanguard Group Inc. Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Stifel maintains 'Buy' on Lexeo stock, confident amid trial progress By Investing.com - Investing.com Canada
Chardan Capital Weighs in on Lexeo Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Reaffirmed by Chardan Capital - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - MarketBeat
Q3 2024 Earnings Estimate for Lexeo Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expected to Earn Q3 2024 Earnings of ($0.64) Per Share - Defense World
Royal Bank of Canada Reiterates Outperform Rating for Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Lexeo Therapeutics CEO sells $57.6k in company stock By Investing.com - Investing.com Australia
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $21.00 at HC Wainwright - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares of Stock - Defense World
Lexeo Therapeutics CEO sells $57.6k in company stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given New $21.00 Price Target at HC Wainwright - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Comparing Cognition Therapeutics (NASDAQ:CGTX) & Lexeo Therapeutics (NASDAQ:LXEO) - Defense World
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - InvestorPlace
LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024 - MSN
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - StockTitan
Lexeo Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
American International Group Inc. Invests $79,000 in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):